-
Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial
-
Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
-
Assessing the potential of EEG as a biomarker in Huntington’s disease using machine learning automatic classification
-
Assessing the Quality of Economic Evaluation of Treatment Options for Parkinson’s disease Using the Quality of Health Economic Studies (QHES) Scale
-
Assessing working memory dysfunction with letter n-back functional MRI task in early-stage Parkinson’s disease
-
Assessment of clinical peculiarities of violations of vertical vision in patients with Parkinson’s disease
-
Assessment of cognitive functions, depression-anxiety scales and quality of life in patients and their relatives with Cervical Dystonia and Botulinum Toxin Treatment
-
Assessment of CSF biomarkers clinical value in Progressive Supranuclear Palsy
-
Assessment of Motor Symptoms in Parkinson’s disease using Flexible Wearable Sensors and Deep Neural Networks: A CIS-PD substudy
-
Assessment of pain and its correlation with quality of life in Parkinson’s disease
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 177
- Next Page »